Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.
KMID : 0370220040480010001
Yakhak Hoeji
2004 Volume.48 No. 1 p.1 ~ p.5
Pharmacokinetic Interaction between Nifedipine and Paclitaxel in Rats
ÃÖÁؽÄ/Choi JS
ÀÌÁ¾±â/Lee JK
Abstract
The purpose of this study was to investigate the effect of coadministration and 3 days-pretreatmemt of nifedipine (2, 10 mg/kg) on the pharmacokinetic parameters and bioavaila bility of paclitaxel (50 mg/kg) after oral administration in rats. Coadministration of nifedipine with paclitaxel did alter the Cmax (l15¡¾29 ng/ml without nifedipine; 135¡¾35 ng/ml with nifedipine (10 mg/kg); p<0.05) and AUC (188¡¾459 ng/ml¡¤hr without nifedipine; 2546¡¾642 ng/ml¡¤hr with nifedipine; p<0.05). Three days treatment of nifedipine on the prior to paclitaxel administration increased the t1/2[9.90¡¾2.47 hr without nifedipine; 12.37¡¾3.12 hr with nifedipine (2 mg/kg); 12.83¡¾3.32 hr with nifedipine (10 mg/ml); p<0.05] and AUC [1833 ¡¾459 ng/ml¡¤hr without nifedipine; 2663¡¾648 ng/ml¡¤hr with nifedipine (2 mg/kg); 3006¡¾734 ng/ml¡¤hr with nifedipine (10 mg/ml); p<0.05]. Drug interaction between nifedipine and paclitaxel decreased the elimination rate constant and increased the oral bioavailability of paclitaxel. On the basis of the results of this study, it might be considered that nifedipine may inhibit cytochrome P45O, which are engaged in paclitaxel metabolism, result in increased t1/2 and AUC of paclitaxel. Howeverl further study should be conducted to clarify the roles of cytochrome P45O and P-glycoprotein on paclitaxel bioavailability with/or without nifedipine.
KEYWORD
FullTexts / Linksout information
Listed journal information
ÇмúÁøÈïÀç´Ü(KCI)